Venus Concept Inc. (NASDAQ:VERO) Q1 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals significant challenges: a 22% revenue decline, increased operating loss, and lack of full-year guidance. Despite debt reduction and strategic shifts, the market conditions and financial strain are concerning. The Q&A highlighted uncertainties, particularly around tariffs and sales delays. While there is potential with the new product, the lack of specifics and distributor hesitancy add to the negative sentiment. Without a clear shareholder return plan and with financial metrics pointing to struggles, the stock is likely to experience a negative reaction.
Key Financial Performance
Total Revenue $13.6 million, down $3.8 million or 22% year-over-year due to delays in system sales and distributor ordering patterns.
International Revenue Decreased by 29% year-over-year, contributing to the overall revenue decline.
U.S. Revenue Decreased by 16.5% year-over-year, impacted by customer financing pressures and economic uncertainty.
Gross Profit $8.8 million, down $2.9 million or 25% year-over-year, primarily due to tighter third-party lending practices and decreased international revenue.
Gross Margin 54.2% of revenue, down from 66.6% of revenue for Q1 2024.
Total Operating Expenses $18.3 million, decreased by $1.1 million or 6% year-over-year due to cost containment efforts.
GAAP Operating Loss $9.5 million, compared to $7.8 million in Q1 2024.
Net Interest and Other Expenses $2.5 million, compared to $2 million in Q1 2024, driven by a noncash loss on debt extinguishment.
Net Loss Attributable to Stockholders $12.4 million or $17.44 per share, compared to a net loss of $9.8 million or $16.91 per share in Q1 2024.
Adjusted EBITDA Loss $8.3 million, compared to an adjusted EBITDA loss of $5.1 million in Q1 2024.
Cash and Cash Equivalents $3.2 million as of March 31, 2025, down from $4.3 million as of December 31, 2024.
Total Debt Obligations Approximately $35.5 million, down from approximately $39.7 million as of December 31, 2024, representing a $4.2 million reduction.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Product Launch: We are actively working on evolving our portfolio and look forward to announcing our next body device in the second half of 2025.
Market Expansion: Our international results reflect the impact of disruptive distributor ordering patterns due to hesitancy from distributor partners amid global macro headwinds.
Market Positioning: We continue to believe that our efforts to reposition the business to prioritize cash system sales is the right strategy to enhance the company’s long-term profitability profile.
Operational Efficiency: Total operating expenses decreased $1.1 million or 6% to $18.3 million, reflecting progress in cost containment and streamlining operations.
Strategic Shift: We are managing our cash burn through disciplined cost management and making targeted investments to support our long-term growth.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Decline: First quarter revenue declined 22% year-over-year, primarily due to delays in new system sales and a 25% decline in systems revenue.
Market Conditions: Current market conditions present uncertainty regarding the timing and pace of new system adoption in both U.S. and international markets.
Customer Financing Pressures: Economic uncertainty, higher interest rates, and tighter credit markets are impacting customer system adoption.
Distributor Hesitancy: Disruptive distributor ordering patterns due to hesitancy from distributor partners amid global macro headwinds and trade concerns.
Gross Profit Decline: Gross profit decreased 25% due to tighter third-party lending practices and decreased revenue in international markets.
Operating Loss: GAAP operating loss increased to $9.5 million, reflecting ongoing challenges in the business environment.
Debt Obligations: Total debt obligations were approximately $35.5 million, indicating financial strain and reliance on debt management.
Lack of Financial Guidance: The company is not providing full year 2025 financial guidance due to ongoing market conditions and trade disruptions.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Strategic Priority: Transition the company to a higher quality cash revenues, with cash system sales in the U.S. representing 80% of total U.S. system sales in Q1 2025.
Product Focus: Prioritizing core products in the U.S., including BlissMAX, Versa Pro, and Viva MD to improve sales efficiency.
International Strategy: Evolving the OUS commercial strategy to enhance future growth and profitability.
New Product Launch: Anticipating the announcement of a new body device in the second half of 2025.
Cost Management: Managing cash burn through disciplined cost management and targeted investments.
Market Opportunity: Highlighting the complementary benefits of body technology, specifically skin tightening, to consumers using GLP-1 medications.
Revenue Expectations: The company is not providing full year 2025 financial guidance due to ongoing market conditions but expects sequential revenue growth in Q2 2025.
Debt Management: Reduced total debt obligations by $4.2 million in Q1 2025.
Cash Position: As of March 31, 2025, cash and cash equivalents were $3.2 million.
Future Financing: Increased financing capacity by $10 million through a bridge loan amendment with Madryn Asset Management.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: The company did not mention any share repurchase program during the call.
Dividend Program: The company did not discuss any dividend program during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How do you expect recently enacted and proposed tariffs to impact your business as we move throughout 2025?
A:The tariffs related to Israel are about 10% at this stage, which could impact our gross margins by 1% to 1.5% in 2025 and 2% to 2.5% in 2026. The robotics business will see a similar impact. Overall, the actual impact of the tariffs will be modest and manageable through pricing, but there is economic uncertainty causing distributors to be hesitant in their purchasing.
Q:Were the sales that were pushed into the second quarter mostly related to U.S. sales or international distributors?
A:It’s a combination of both U.S. sales and international distributors, tied to economic conditions causing hesitancy. Sales often happen at the end of the quarter, and deal negotiations extending can push sales beyond the quarter's end.
Q:Can you provide an update on the timeline for the next-gen body contouring device?
A:We expect the approval and launch in the early part of the second half of the year. The regulatory process is underway, and there’s no reason to believe the timing will extend. There is customer excitement about the device, and we expect meaningful market uptick.
Q:Review of Unclear Management Responses
A:Management's response regarding the impact of tariffs was somewhat vague, particularly in terms of how they plan to mitigate the impact on margins. Additionally, while they mentioned customer excitement for the next-gen device, they did not provide specific details on the product or its features.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Accepted Accounting
Accounting Principles
BlissMAX Versa
Domenic Della
Domenic depth
Domenic review
Mr Chief
Officer Domenic
Principles measure
Pro sale
Transcript day
Venus Domenic
Versa Pro
accordance Accepted
adoption environment
adoption market
amendment equity
burn cost
capital transaction
cash burn
challenging environment
concern fluctuation
condition debt
condition question
condition sale
core product
cost investment
creation opportunity
customer engagement
deal system
debt equity
delay timing
device cash
equipment environment
VERO Transcript
Venus Concept Inc. (VERO) Q3 2025 Earnings Call Transcript
Unknown11-13
The company's financial performance shows declining revenue and increased losses, with challenges in the hair restoration business and economic uncertainties. Despite some positive developments, such as the sale of the Venus Hair business and strategic focus on growth, the lack of guidance and increased debt obligations weigh negatively. The absence of Q&A insights further limits positive sentiment. Overall, the negative financials and uncertainties overshadow potential growth catalysts, leading to a negative outlook.
Venus Concept Inc. (VERO) Q2 2025 Earnings Call Transcript
Unknown8-14
The earnings call summary indicates several negative factors: declining international sales, supply chain disruptions, a significant drop in gross margin, increased operating expenses, and widening losses. Although there is some positive news, such as the sale of the Venus Hair business and a slight increase in U.S. revenue, the overall financial health and strategic uncertainties outweigh these. The lack of full-year guidance and high debt obligations further contribute to a negative outlook, likely leading to a stock price decline of -2% to -8% over the next two weeks.
Venus Concept Inc. (NASDAQ:VERO) Q1 2025 Earnings Call Transcript
Unknown5-16
The earnings call reveals significant challenges: a 22% revenue decline, increased operating loss, and lack of full-year guidance. Despite debt reduction and strategic shifts, the market conditions and financial strain are concerning. The Q&A highlighted uncertainties, particularly around tariffs and sales delays. While there is potential with the new product, the lack of specifics and distributor hesitancy add to the negative sentiment. Without a clear shareholder return plan and with financial metrics pointing to struggles, the stock is likely to experience a negative reaction.
Venus Concept Inc. (VERO) Q1 2025 Earnings Call Transcript
Unknown5-15
The earnings call reflects a negative sentiment due to several factors: a significant revenue decline (22% YoY), increased operating losses, and a lack of financial guidance for 2025. The Q&A revealed concerns about tariffs and unclear management strategies, adding to uncertainties. Although debt was reduced and a new product launch is anticipated, these positives are overshadowed by weak financial performance and market challenges. Without share repurchases or dividends, shareholder returns are stagnant. These factors suggest a likely negative stock price reaction in the short term.
VERO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
